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Abstract Tau proteins are abnormally phosphorylated in Alz- 
heimer's disease. Pathological Tau proteins named PHF-Tau 55, 
PHF-Tau 64, and PHF-Tau 69, are the main constituents of the 
paired helical filaments (PHF). When treating SKNSH-SY 5Y 
cells with okadaic acid (OA), Tau 55 protein was clearly induced 
whereas Tau 64 protein was only faintly induced. Here, we show 
that the absence of Tau 69 could be explained by the fact that 
adult isoforms containing N-terminal inserts are not detected. 
Phosphorylation is similar for untreated cellular Tau proteins and 
fetal Tau proteins, while OA cell treatment ransformed fetal- 
type into Alzheimer-type phosphorylated proteins. 
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1. Introduction 
Tau proteins are microtubule-associated proteins of 50,000- 
64,000 Da, mainly found in axons of neurons. In human, six 
isoforms arise by alternative splicing of a primary transcript 
originating from a single gene [1]. Exons 2, 3 and 10 (nomencla- 
ture according to Andreadis's paper [2]) are under developmen- 
tal regulation and they are only expressed in some adult 
isoforms. The fetal isoform (FF) (which expresses no exon 
among the alternatively expressed exons) is found in both fetal 
and adult brains. The other five isoforms found in adult brain 
correspond to the fetal isoform modified by insertions corre- 
sponding to the expression of 1, 2 or 3 alternative xons, i.e. 
the exons 2, 3, and 10 [1]. In this paper, these isoforms are 
named FF-10; FF-2; FF-2,10; FF-2,3 and FF-2,3,10 according 
to the expressed alternative xon (as described in Fig. 1). 
In Alzheimer's disease, abnormal phosphorylation of Tau 
proteins leads to their aggregation i paired helical filaments 
(PHF) [3,4]. All six isoforms are abnormally phosphorylated 
and then migrate in SDS-polyacrylamide gels as a triplet named 
PHF-Tau 55, PHF-Tau 64 and PHF-Tau 69. Both Goedert et 
al. [5] and Brion et al. [6] have identified the lower PHF-Tau 
band (here named PHF-Tau 55) as the abnormally 
phosphorylated Tau molecules containing neither exon 2 nor 
3 (i,e. FF  and FF-10). The upper band (here named PHF-Tau 
69) was identified as the phosphorylated products of Tau pro- 
teins containing exon 2 and exon 3 (i.e. FF-2,3 and FF-2,3,10) 
[5]. The middle band (here named PHF-Tau 64) would corre- 
spond to the abnormally phosphorylated isoforms containing 
exon 2 (i.e. FF-2 and FF-2,10). The distribution of the different 
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isoforms in the triplet, as proposed by Goedert et al. [5], is 
shown in Fig. 1. 
The mechanisms leading to abnormal phosphorylation are 
unknown. Some purified members of the proline-directed pro- 
tein kinase family (MAP kinase, cyclin-dependent kinase, 
GSK3 kinase) were successfully tested for their capacity to 
phosphorylate in vitro Tau proteins and to generate Alzheimer- 
type epitopes [7-12]. The molecular weight of in vitro 
phosphorylated Tau protein and PHF-Tau triplet was only 
compared in the two following systems. First, in human brain 
slices treated by okadaic acid (OA), an inhibitor of protein 
phosphatases-1 and -2A [13], PHF-Tau triplet was induced: 
Tau 64 band was mainly detected at low OA concentrations 
whereas Tau 55 and Tau 69 only appeared at higher OA con- 
centrations [14]. Second, in NGF-differentiated SKNSH-SY 
5Y cells treated by OA, only Tau 55 and Tau 64 were detected, 
Tau 55 being the major band and Tau 64 the minor one [15,16]. 
The differences between the two systems could be due to a 
different ratio between the Tau isoforms present. According to 
Goedert et al.'s results [1] (Fig. 1), in OA treated cells, the 
absence of Tau 69 might be due to the lack of isoforms contain- 
ing exons 2 and 3 (i.e. FF-2,3, FF-2,3,10 isoforms). In a similar 
way, the low quantity of Tau 64 might reflect a low quantity 
of Tau isoform(s) with exon 2 (FF-2 and FF-2,10 ). To verify 
this assumption, we characterized the Tau isoforms present in 
our cell model by biochemical nd molecular biology methods. 
Here, we show that cellular Tau proteins are similar to fetal Tau 
proteins and that adult isoforms containing N-terminal inserts 
are not detected in SKNSH-SY 5Y. Moreover, the treatment 
of the neuroblastoma cells by OA allowed a shift from fetal- 
type to Alzheimer-type phosphorylated proteins. 
2. Materials and methods 
2.1. Cell cultures, cell- and Alzheimer brain extracts 
SKNSH-SY 5Y cells were maintened in Dulbecco's modified Eagle's 
medium (DMEM) (Boehringer, Mannheim) supplemented with 10% 
fetal calf serum. Differentiation, OA treatment, and cell extraction were 
performed as described in [16]. Briefly, NGF-differentiated cells were 
treated with 0.25/IM OA for 6 h over 4 days, Cells and brain tissues 
were homogenized in Laemmli's buffer with 0.25% dithiothreitol, and 
heat treated before loading onto polyacrylamide g ls. 
2.2. PAGE and Western blotting 
Electrophoresis, transfer, Ponceau red staining and Western blotting 
were performed as described in [16]. The antibodies used were: the 
absorbed anti-PHF serum (abs PHF) (specific for PHF-Tau [4]), the 
polyclonal mino-terminal T u serum (N-term) (specific for both Alz- 
heimer and normal Tau proteins [16]), Tau 1 antibodies ( pecific for 
normal Tau [17,18]), AT8 (from Innogenetics, pecific for Alzheimer- 
type Tau proteins [19]) and AD2 (monoclonal ntibody specific for an 
abnormal site of phosphorylation in Alzheimer Tau proteins (V. Bu6e 
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et al., manuscript in preparation)). Tau 1 and AT8 are located in the 
same region (amino acids 198-202) but AD2 is located in the C-terminal 
part of the Tau molecule. After incubation with the anti-rabbit or 
anti-mouse antibodies conjugated with peroxydase (Diagnostic Pas- 
teur), visualization was performed using the ECL (Enhanced chemilu- 
minescence) detection kit from Amersham. 
2.3. Alkaline phosphatase treament 
OA cell extracts were dialysed against a buffer containing 50 mM 
Tris, pH 8.3, 50 mM NaC1, 1 mM MgC12 and 0.2 mM DTT, overnight 
at 4°C, and were dephosphorylated using calf intestine alkaline phos- 
phatase (Boehringer, Mannheim) at 100 U/ml as described by Flament 
and Delacourte [20]. 
2.4. mRNA isolation and reverse transcriptase-polymerase chain 
reaction 
Total cellular RNA was extracted by the RNAzol B method (Cinna/ 
Biotecx) according to the manufacturer's in tructions. For first-strand 
cDNA synthesis, 10,ul reaction mixture contained the provided enzyme 
buffer, 1.5/tg of total RNA, 20 pM of reverse primer, 100 U of reverse 
transcriptase Mu-MLV, 2.5 mM deoxynucleotide triphosphates and 
1 ¢tg serum albumin. The reaction mixture was first incubated at 80°C 
for 5 min, then at 37°C for 90 min. For the 100/ll PCR mixture, 1 U 
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of TaqI polymerase, 20 pM of forward primer and the provided Taql 
buffer were added to the 10/11 of reverse transcription reaction mixture. 
Forward and reverse primers were located, respectively, in exon 1 and 
in exon 4, i.e. on each side of the alternatively expressed exons 2 and 
3 and corresponded, respectively, to bases 5' TACGGGTTGGGGG- 
ACAGGAAAGAT 3' and to bases 5'GGGGTGTCTCCAATGCCT- 
GCTTCT 3'. PCR was carried out in a Perkin Elmer thermal cycler 
using cycles consisting of denaturation at94°C for 1 min, followed by 
annealing at 65°C for 1 min and DNA extension at 72°C for 2 rain for 
30 cycles. The obtained DNA was characterized by gel agarose or 
acrylamide lectrophoresis, digestion with endonuclease restriction and 
cDNA sequencing. 
2.5. cDNA sequencing 
The ampligen was first cloned into pBluescript II SK (Stratagene), 
then sequenced with the Sequenase Kit (USB) following the manufac- 
turer's protocol. 
3. Resu l ts  and d iscuss ion 
The electrophoretic pattern of SKNSH-SY 5Y cell Tau pro- 
teins was compared with that of fetal, adult and Alzheimer 
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Fig. 1. Correspondance b tween pathological Tau triplet and different Tau isoforms according to Goedert et al. [1,6]. The exon numbers are indicated 
according to Andreadis et al.'s nomenclature [2]. 
Homogenates + Phosphatases 
Q Q Brains Cells 
Brains Cells IAIz Ctrl AIz F II I 
IAIz Ctrl F I r f f~ff l  _ + _ + I _  + - +1 - + 
69 kDa 
64  kDa ~ 
55 kDa 55  kDa [ t~ 
Fig. 2. Western blot analysis of homogenates from brains and SKNSH-SY 5Y cell cultures. (A) Electrophoretic pattern of Tau proteins from 
Alzheimer (Alz), control (Ctrl) and fetal (F) brain homogenates and from 4 days NGF-differentiated (D) or not differentiated (ND) cell homogenates. 
SKNSH-SY 5Y Tau proteins migrated as fetal Tau proteins. (B) Migration of Tau proteins from brain (Alz, Ctrl, F) and differentiated cell (Cell) 
homogenates before (-) or after phosphatase treatment (+). Two fetal Tau proteins were revealed after two different exposure times. Tau proteins 
in A and B were revealed by N-term serum. 
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Fig. 3. Analysis of the exons 2 and 3 presence in SKNSH-SY 5Y Tau mRNA. (A) Drawing of the studied region indicating the restriction enzyme 
sites and the sizes of PCR products corresponding to the different possibilities of splicing. (B) RT-PCR product of Ctrl and OA treated-cells. Marker 
1, DNA ladder from BRL. (C) Enzyme restriction analysis of the 110 bp band. Plasmid pblcat5 cut by HaelII or HinfI enzymes was used as the 
size marker (respectively marker 2 and marker 3). 
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Fig. 4. Alzheimer specific antibodies' immunoreactivity onnon-treated (-) and OA-treated (+) cells. NGF-differentiated cells were treated with 0.25 
/zM OA for 6 h over 4 days. Tau 64 was only detected with the N-term and abs PHF polylonal antibodies whereas Tau 55, the major band, was 
also detected by AT8 and AD2 monoclonal antibodies. 
brains. As seen in Fig. 2A, fetal and cell Tau proteins migrated 
in a similar way. By comparison of Tau patterns of fetal and 
cellular samples after alkaline phosphatase, we confirm a simi- 
lar migration for both dephosphorylated f tal and cellular Tau 
proteins (Fig. 2B). Therefore, the result of alkaline phosphatase 
treament demonstrates a similar phosphorylation degree and 
the presence of the same isoforms in cellular and fetal Tau 
proteins. Cellular Tau protein did not then contain the N- 
terminal inserts. 
To ascertain the absence of isoforms containing exons 2 and 
3 in SKNSH-SY 5Y cells, we examined the 5' extremity of 
cellular mRNA by RT-PCR. Using primers on each side of 
exon 2 and 3, only one amplified product of about 110 bp was 
obtained (Fig. 3B) and corresponded to the size expected in the 
absence of exons 2 and 3 (Fig. 3A). The restriction enzyme 
digestion profile effectively corresponded to this isoform (Fig. 
3C). This result was confirmed by cloning and sequencing this 
band of 110 bp. The sequence was identical to the one published 
by Goedert et al. [21] and confirmed the absence ofexons 2 and 
3 in this DNA and then in the cellular mRNA (not shown). 
Nevertheless, i oforms containing exons 2 and 3 could be newly 
synthesized uring OA treatment. To check this point, RT- 
PCR analysis was performed on mRNA prepared from OA 
treated cells. The absence of exons 2 and 3 was confirmed since 
no new band was detected (Fig. 1B). 
In SKNSH-SY 5Y cells, only the isoform without exons 2 
and 3 was detected unless both Tau 55 and Tau 64 (correspond- 
ing to isoforms without exon 2 and to isoforms with exon 2, 
according to Goedert et al.'s results [5]) were induced when 
treating cells with OA ([16] and Fig. 3). Tau 55 was the major 
band, Tau 64 the minor one. Thus, in OA treated cells, the 
detection of Tau 64 did not seem to be due to the phosphoryl- 
ation of the exon 2-containing isoform as reported for PHF- 
Tau 64 by Goedert et al. [5]. Then, Tau 64 detection might then 
be due to a hyperphosphorylation of the 55 kDa band. This 
would support he idea of the existence of different states of 
phosphorylation of the same isoform. Such a hypothesis is 
compatible with (i) the observation reported by Ksiezak-Red- 
ing et al. [22] that phosphatase treatment of PHF-Tau proteins 
induced a relative increase in the immunoreactivity of Tau 
64 polypeptide and a decrease in the immunoreactivity of the 
Tau 69 band; and (ii) a multiple step phosphorylation f Tau 
proteins by in vitro kinase assays [7,10]. 
Some common phosphorylation sites were described be- 
tween fetal and Alzheimer Tau molecules [23-27]. Fetal Tau 
phosphorylation is highly heterogeneous and only a proportion 
of fetal Tau molecules i  phosphorylated in the majority of the 
Alzheimer common sites. Since in SKNSH-SY 5Y cells, fetal- 
type Tau proteins were mainly detected (this paper), it was 
important to know if the Tau phosphorylation induced by OA 
treatment [16] was more related to a fetal stage or to a pa- 
thological phosphorylation. I  untreated SKNSH-SY 5Y cells, 
Tau proteins are already phosphorylated, as shown by the 
action of phosphatase on Tau migration (Fig. 2B). Tau protein 
phosphorylation degree seemed similar to fetal phosphoryla- 
tion since we observed a similar migration of both proteins 
before and after phosphatase treatment (Fig. 2B). Indeed, de- 
tection by Tau 1 was increased by phosphatase treatment, (not 
shown) then some of the Tau 1 sites must already be 
phosphorylated before OA treament. This was confirmed by 
AT8 binding to control cellular Tau proteins (Fig. 4). In the 
same way, a weak AD2 immunoreactivity is seen on control 
Tau proteins (Fig. 4). Thus, like fetal Tau proteins, cellular Tau 
proteins are partially phosphorylated in some Alzheimer spe- 
cific sites. Yet OA treatment induced a hyperphosphorylation 
and the OA-modified Tau protein electrophoretic migration 
was very similar to Tau 55 and Tau 64 migration of the Alz- 
heimer triplet as described in [16]. After treatment, all the Tau 
1 sites were phosphorylated since Tau proteins were no longer 
detected by Tau 1 antibodies. We also observed a clear increase 
of Tau 55 phosphorylation in Alzheimer-specific AT8 and AD2 
sites after OA treatment on Tau 55 (Fig. 4). We did not succeed 
in obtaining the same strong immunodetection f Tau 55 with 
the AT8 and AD2 monoclonal antibodies as with the N-term 
and abs PHF polyclonal sera (perhaps because of the antibod- 
ies' concentration). This might explain why the minor Tau 64 
band was only detected by using polyclonal sera. 
In the OA treated cells, the apparent molecular weight 
change, the loss of Tau 1 immunoreactivity and the increased 
detection of Alzheimer epitopes on Tau molecules are in favour 
of a shift from fetal-type into Alzheimer-type phosphorylated 
Tau proteins. These results further reinforce the value of our 
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SKNSH-SY 5Y model for the in vitro study of Alzheimer-type 
Tau phosphorylation mechanisms. 
Acknowledgements. We are very grateful to Dr. A. Van de Voorde 
(Innogenetics) for the gift of AT8 antibody, and to V. Bu6e-Scherrer 
and Dr. B. Pau for AD2 antibody. We also wish to thank Dr. M.C. 
Chartier-Harlin for helpful discussions. RT-PCR was accomplished in 
Dr. M.H Loucheux's laboratory (INSERM Unit6 124, Lille, France). 
References 
[1] Goedert, M., Spillantini, M.G., Potier, M.C., Ulrich, J. and 
Crowther, R.A. (1989) EMBO J. 8, 393-399. 
[2] Andreadis, A., Brown, W.M. and Kosik, K.N. (1992) Biochem. 31, 
1062610633. 
[3] Iqbal, K., Grundke-Iqbal, I. Zaidi, T., Merz, P.A., Wen, G.Y., 
Shaikh, S.S., Wisniewski, H.M., Alafuzoff, I. and Winblad, B. 
(1986) Lancet 2, 421-426. 
[4] Delacourte, A., Flament, S., Dibe, E.M., Hublau, P., Sablonni6re, 
B., Hemon, B., Scherrer, V. and D6fossez, A. (1990) Acta Neu- 
ropathol. 80, 111-117. 
[5] Goedert, M., Spillantini, M.G., Cairns, N.J. and Crowther, R.A. 
(1992) Neuron 8, 159-168. 
[6] Brion, P., Hanger, D.P., Couck, A.M. and Anderton, B.H. (1991) 
Biochem. J. 279, 831-836. 
[7] Drewes, G., Lichtenberg-Kraag, B., D6ring, F., Mandelkow, 
E.M., Biernat, J., Goris, J., Dor6e, M. and Mandelkow, E.M. 
(1992) EMBO J. 11, 2131-2138. 
[8] Hanger, D.P., Hughes, K., Woodgett, J.R., Brion, J.P. and Ander- 
ton, B.H. (1992) Neurosci. lett. 147, 58-62. 
[9] Ledesma, M.D., Correas, I., Avila, J. and Diaznido, J. (1992) 
FEBS lett. 308, 218-224. 
[10] Mandelkow, E.M., Drewes, G., Gutske, N., Van Lint, J., Vanden- 
heede, J.R. and Mandelkow, E. (1993) FEBS lett. 314, 315-321. 
[11] Vulliet, R., Halloran, S.M., Braun, R.K., Smith, A.J. and Lee, G. 
(1992) J. Biol. Chem. 267, 22570-22574. 
[12] Baumann, K., Mandelkow, M.E., Biernat, J., Piwnica,Worms, H.
and Mandelkow, E. (1993) FEBS lett. 336, 417424. 
[13] Cohen, P., Holmes, C.F.B. and Tsukitani, Y. (1990) Trends Bio- 
chem. Sci. 15, 98-103. 
[14] Harris, K.A., Oyler, G.A., Doolittle, G.M., Vincent, I., Lehman, 
R.A.W., Kincaid, R.L. and Billingsley, M.L. (1993) Ann. Neurol. 
33, 77-87. 
[15] Sauti6re, P.E., Caillet-Boudin, M.L., Wattez, A., Bu6e-Scherrer, 
V., and Delacourte, A. (1993) C. R. Acad. Sci. Paris 316, 533-535. 
[16] Sauti+re, P.E., Caillet-Boudin, M.L., Wattez, A. and Delacourte, 
A. (1993) Neurodegeneration 3, 53-60. 
[17] Ksiezak-Reding, H., Binder, L.I. and Hen, S.H. (1990) J. Neu- 
rosci. Res. 25, 420-430. 
[18] Lee, V.M., Balin, B. J., Otvos Jr., L. and Trojanowski, J.Q. (1991) 
Science 251,675~578. 
[19] Biernat, J., Mandelkow, E.M., Schr6ter, C., Lichtenberg-Kraag, 
B., Berling B., Meyer, H., Mercken, M., Vandermeeren, A., Goe- 
dert, M. and Mandelkow, E. (1992) EMBO J. 11, 1593-1597. 
[20] Flament, S. and Delacourte, A. (1989) FEBS Lett. 247, 213 216. 
[21] Goedert, M., Wischik, C.M., Crowther, R.A., Walker, J.E. and 
Klug, A. (1988) Proc. Natl. Acad. Sci. USA, 85, 4051-4055. 
[22] Ksiezak-Reding, H., Liu, W.K. and Yen, S.H. (1992) Brain Res. 
597, 209-219. 
[23] Kanemaru, K., Takio, K., Miura, R., Titani, K. and Ihara, Y. 
(1993) J. Neurochem. 58, 1667-1675. 
[24] Hasegawa, M., Watanabe, A., Takio, K., Suzuki, M., Arai, T., 
Titani, K. and Ihara, Y. (1993) J. Neurochem. 60, 2068-2077. 
[25] Bramblett, G.T., Goedert, M., Jakes, R., Merrick, S.E., Trojanow- 
ski, J.Q. and Lee, V.M.M. (1993) Neuron, 10, 1089-1099. 
[26] Goedert, M., Jakes, R., Crowther, R.A., Six, J., Ltibke, U., Van- 
dermeeren, M., Cras, P., Trojanowski, J.Q. and Lee, V.M. (1993) 
Proc. Natl. Acad. Sci. USA 90, 5066-5070. 
[27] Watanabe, A., Hasegawa, M., Suzuki, M., Takio, K., Morishima- 
Kawashima, M., Titani, K., Arai, T., Kosik, K.S. and Ihara, Y. 
(1993) J. Biol. Chem. 268, 25712-25717. 
